In clinical trials, CTLA-4 inhibitors given before or with RT did not improve brain metastases; this may be due to the brain’s unique role as an immune-privileged site; however, in advanced-stage metastatic melanoma, non-brain RT in conjunction with CTLA-4 inhibitors significantly improved survival time [6]. This evidence concerns the gene CTLA4 and metastatic melanoma.